For 12 years, the FDA and the Drug Enforcement Administration have been studying whether to move medicines containing hydrocodone from the Schedule III category to the more restrictive Schedule II.
ED visits related to use of non-medical hydrocodone rose from 19,221 in 2000 to 86,258 in 2009.
Related Articles on Hydrocodone:
Utah Orthopedic Surgeon Defends Use of Pain Meds During Trial
Drugmakers Recall Certain Oxycodone, Hydrocodone Pills
Boca Pharmacal Receives FDA Approval of Generic Drug for Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.